{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"16","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Overall survival is defined as the time from study entry until death from any cause.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nsorafenib tosylate: Given orally","id":"OG000","title":"Treatment (Sorafenib)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Assessed after month 2 and month 6, then every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, up to 3 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}